GET DAILY SIGNALSDirexion Daily LLY Bull 2X ETF (ELIL) Climbs +48% Over 30 Days on Eli Lilly Momentum
Key Takeaways
- ELIL rose roughly 48% over the last 30 days, climbing from a close near $27.88 on October 13 to approximately $41.29 in mid-November.
- The rally was powered by Eli Lilly's third-quarter 2026 results, which beat estimates and drove the underlying LLY stock sharply higher.
- As a 2x daily leveraged fund, ELIL seeks to deliver roughly twice the daily return of Eli Lilly shares, amplifying both gains and losses.
- Strong demand for the GLP-1 treatments Mounjaro and Zepbound was the central catalyst behind the underlying equity's advance.
- The last quarter was volatile: ELIL slid to a mid-September low near $26 before rebounding to the low-$40 range.
- Leveraged single-stock products carry compounding and volatility risks and are generally designed for short-term trading horizons.
ELIL Overview: A Leveraged Play on Eli Lilly
ELIL is the Direxion Daily LLY Bull 2X ETF, a leveraged single-stock exchange-traded fund that seeks daily investment results, before fees and expenses, of 200% of the daily performance of the common shares of Eli Lilly and Company (LLY). Launched in March 2025 and managed by Rafferty Asset Management, the fund gains its exposure primarily through derivatives such as swaps and options rather than by holding large positions in the underlying equity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Because its objective resets daily, ELIL is designed for traders seeking amplified short-term exposure to Eli Lilly rather than for buy-and-hold investors. The fund's performance is closely tied to the pharmaceutical giant's leadership in diabetes and obesity treatments, particularly its incretin-based therapies. Investors follow ELIL as a high-beta, high-volatility way to express a view on Eli Lilly's share price over short horizons.
ELIL Stock Performance: Recent 30-Day Surge and Quarterly Volatility
Over the last 30 days, ELIL advanced approximately 48%, rising from a closing price near $27.88 on October 13 to roughly $41.29 in mid-November. The steepest leg of the move came in late October, when the fund surged from about $33.91 on October 28 to $38.13 on October 29—a single-session gain of more than 12%—as the underlying Eli Lilly shares rallied on earnings. The broader quarterly trend was more uneven. Over roughly the past three months, ELIL rose about 20%, but that headline gain obscures significant volatility. From the mid-$34 level in mid-August, the fund declined to a September low near $26 before reversing sharply higher on improved sentiment around Eli Lilly and its weight-loss and diabetes franchise. The result was a strong recovery into November that left the fund trading well above its quarterly starting point.
What Fueled the Recent 30-Day Advance in ELIL
The dominant catalyst was Eli Lilly's third-quarter 2026 earnings report, released on October 29. The company reported revenue of about $24.4 billion, up 39% year over year and above Wall Street's consensus of roughly $22.6 billion, while adjusted earnings per share of $7.48 also beat estimates. Management raised its full-year revenue guidance to a range of $91 billion to $92 billion, up from a prior $85 billion to $87 billion. Growth was driven by surging demand for Mounjaro, whose global sales rose 65% to roughly $10.7 billion, and Zepbound, which grew 49% to about $5.4 billion. The two products together accounted for the bulk of quarterly revenue. Eli Lilly shares jumped more than 6% on the report and touched a record high, and ELIL's 2x daily leverage roughly doubled that move in a single session. The sharp rally in the underlying equity—rather than any change in the fund's own mechanics—is the primary explanation for ELIL's 30-day advance.
Quarterly Drivers Behind ELIL's Uneven Path
The quarterly picture reflects the underlying volatility of Eli Lilly's shares compounded by daily leverage. Earlier in the period, ELIL weakened alongside a pullback in the broader healthcare and pharmaceutical complex, sliding from the mid-$30s into the mid-$20s by mid-September. Investor attention was focused on competition in the GLP-1 space from NVO and on the early launch trajectory of newer oral obesity treatments. Sentiment shifted in October as expectations built ahead of Eli Lilly's quarterly report. The subsequent earnings beat and raised guidance re-established confidence in the company's leadership in metabolic medicine, and the fund's leveraged structure translated that renewed enthusiasm into an outsized recovery. The combination of a mid-quarter drawdown and a late-quarter surge illustrates how leveraged funds can lag or lead their underlying index over longer periods because of daily compounding.
Factors to Monitor for ELIL Going Forward
Because ELIL's returns are driven by daily moves in Eli Lilly shares, the most important factors to monitor are developments affecting the underlying company. Key items include quarterly earnings and guidance updates, prescription volume and pricing trends for Mounjaro and Zepbound, and the commercial uptake of newer oral obesity therapies. Regulatory decisions, Medicare and commercial coverage changes for GLP-1 treatments, and competitive launches from rivals such as NVO could all influence near-term price action. Investors should also account for the structural risks of leveraged products, including daily reset mechanics, compounding effects, and elevated volatility that can cause returns over periods longer than a single day to diverge from double the underlying index's return. As always, these factors are informational in nature and do not constitute financial advice. From what I see, one thing that stands out is how quickly sentiment can shift in this space.
Exploring AI Tools for Leveraged ETF Analysis
In my own research process, I frequently review Tickeron’s AI Trading Bots to compare automated strategies that handle volatile instruments like single-stock leveraged ETFs. The platform highlights top-performing bots from a large library, allowing users to evaluate different approaches based on timeframe and risk metrics without prescribing one specific method. This helps provide context when analyzing products such as ELIL that are sensitive to short-term moves in the underlying equity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ELIL turns positive, indicating new upward trend
ELIL saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator turned positive. In 27 of the 28 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
ELIL moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ELIL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELIL advanced for three days, in 105 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 59 of 62 cases where ELIL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for ELIL moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 8 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ELIL broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
High and low price notable news
Advertisement
Advertisement